Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608934 | 0.96 | GRIN1 (0.39) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL28118949 | 0.93 | EPHX2 (0.39) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL6228624 | 0.86 | GRIN1 (0.58) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL5608342 | 0.86 | CRHBP (0.36) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL5608709 | 0.82 | CRHBP (0.41) | CRHBPCRHR2 | |
| SCHEMBL5608320 | 0.82 | TSHR (0.39) | LMNAEPHX2CRHBPCRHR2MAPT | |
| SCHEMBL6227897 | 0.78 | KMT2A (0.38) | HTTMEN1KMT2AEPHX2MAPT | |
| SCHEMBL14457111 | 0.77 | CRHBP (0.41) | CRHBPCRHR2 | |
| SCHEMBL7173119 | 0.75 | CRHBP (0.45) | CRHBPCRHR2 | |
| SCHEMBL812216 | 0.74 | GRIN1 (0.68) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113735714-A | Preparation method of 3, 5-dimethyl amantadine hydrochloride | 苏州敬业医药化工有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-106187781-B | A kind of preparation method of memantine | 江苏红豆杉药业有限公司 | 2018-07-13 | — | — | CN | claimed |
| CN-106187781-A | A kind of preparation method of memantine | 江苏红豆杉药业有限公司 | 2016-12-07 | — | — | CN | claimed |
| JP-2022129646-A | PRODUCTION METHOD OF MEMANTINE | 国立大学法人 東京大学 | 2022-09-06 | — | — | JP | disclosed |
| CN-113735714-A | Preparation method of 3, 5-dimethyl amantadine hydrochloride | 苏州敬业医药化工有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-106187781-B | A kind of preparation method of memantine | 江苏红豆杉药业有限公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-106187781-A | A kind of preparation method of memantine | 江苏红豆杉药业有限公司 | 2016-12-07 | — | — | CN | disclosed |
| CN-106187781-A | A kind of preparation method of memantine | 江苏红豆杉药业有限公司 | 2016-12-07 | — | — | CN | disclosed |
| CN-103553932-B | Method suitable for industrially preparing memanitine hydrochloride | JIANGSU CHIATAI QINGJIANG PHARMACEUTICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-08-18 | — | — | US | disclosed |
| CN-101412678-B | Method for synthesizing memantine hydrochloride | UNIV SUZHOU | 2011-07-20 | — | — | CN | disclosed |
| WO-2010095041-A2 | COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS | EXCRX (SINGAPORE) PTE.LTD. (SG) | 2010-08-26 | — | — | WO | disclosed |
| CN-101412678-A | Method for synthesizing memantine hydrochloride | UNIV SOOCHOW (CN) | 2009-04-22 | — | — | CN | disclosed |
| US-RE39744-E1 | Adamantane derivatives and process for producing them | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-RE39744-E1 | Adamantane derivatives and process for producing them | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| US-6392104-B1 | CHEMICAL INTERMEDIATES FOR DRUGS, AGRICULTURE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| EP-1099684-A1 | PROCESS FOR THE PREPARATION OF NITRO COMPOUNDS AND METHOD FOR THE REMOVAL OF NITROGEN DIOXIDE | Daicel Chemical Industries, Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
| EP-0927711-A1 | ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THEM | Daicel Chemical Industries, Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | GRIN1 221/4885GRIN2A 80/4885GRIN2D 320/4885 |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | GRIN1 4826/4885GRIN2A 4854/4885GRIN2D 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.